PUBLISHER: TechNavio | PRODUCT CODE: 1544378
PUBLISHER: TechNavio | PRODUCT CODE: 1544378
The tissue engineering and regeneration market is forecasted to grow by USD 28.3 bn during 2023-2028, accelerating at a CAGR of 16.86% during the forecast period. The report on the tissue engineering and regeneration market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic diseases, rising adoption of tissue scaffolds, and increasing initiatives and support from public and private healthcare organizations for cell-based tissue engineering research.
Technavio's tissue engineering and regeneration market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 14.17% |
CAGR | 16.86% |
Incremental Value | $28.3 bn |
By Material
By Application
By Geographical Landscape
This study identifies the emerging technological advances as one of the prime reasons driving the tissue engineering and regeneration market growth during the next few years. Also, increasing number of clinical trials and increasing strategic partnerships and acquisitions in tissue engineering and regeneration will lead to sizable demand in the market.
The report on the tissue engineering and regeneration market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tissue engineering and regeneration market vendors that include 3M Co., AbbVie Inc., Astellas Pharma Inc., B.Braun SE, Baxter International Inc., Becton Dickinson and Co., CO.DON GmbH, Cook Group Inc., Integra Lifesciences Corp., Johnson and Johnson Services Inc., Medtronic PLC, Organogenesis Holdings Inc., Plus Therapeutics Inc., REPROCELL Inc., RTI Surgical Inc., Smith and Nephew PLC, Stryker Corp., Tissue Regenix Group PLC, Vericel Corp., and Zimmer Biomet Holdings Inc.. Also, the tissue engineering and regeneration market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: